This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Identifying Potential Effects of Liraglutide on Degenerative Changes

This study has been completed.
Information provided by (Responsible Party):
University of Aarhus Identifier:
First received: November 1, 2011
Last updated: April 18, 2013
Last verified: April 2013

Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice.

The investigators hypothesis is that a 6-month treatment with the GLP-1 receptor stimulating drug liraglutide will reduce the intracerebral amyloid deposition in the central nervous system (CNS) in patients with Alzheimer's disease (AD) and thereby reduce the clinical symptoms of the disease.

Condition Intervention
Alzheimers Disease Drug: Liraglutide Drug: non-active study drug

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • PIB PET scan [ Time Frame: PIB PET-scan at baseline and after 26 weeks ]
    Primarily to investigate whether 26 weeks of treatment with GLP-1 receptor liraglutide (Victoza ®) will change the intra-cerebral amyloid deposit in the CNS in patients with Alzheimer's disease assessed by PIB PET scan.

Secondary Outcome Measures:
  • Neuro-psychological tests [ Time Frame: At baseline, after 12 weeks and after 26 weeks ]
    To validate the cognitive functions using specific neuro-psychological test battery before and after treatment with liraglutide/placebo.

  • FDG PET Scan [ Time Frame: FDG PET-scan at baseline and after 26 weeks ]
    To examine changes in glucose uptake in the CNS by FDG PET scan before and after 6 months of treatment with liraglutide/placebo

Enrollment: 34
Study Start Date: January 2012
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Drug
the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
Drug: Liraglutide

Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.

Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.

Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.

1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.

Placebo Comparator: placebo
non active intervention
Drug: non-active study drug

  Show Detailed Description


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed consent before study-related activity
  • Adult competent persons
  • Diagnosed with diagnosed Alzheimer's disease. With a MMSE score between 18-21 the diagnosis should be entirely based on the clinic, while diagnosis by MMSE with a score > 22 should be diagnosed by spinal puncture
  • Age ≥ 50 years and ≤ 80 years
  • Caucasians

Exclusion Criteria:

  • Diabetes mellitus
  • Clinically significant liver (s-ALT > 2 times upper reference or creatinine-clearance < 30 mL / min, assessed on Cockcroft-Gault normogram)
  • Clinically significant anemia
  • Other clinically relevant abnormal biochemical value
  • Current or former presence of one of the following diseases with clinical relevance:

    1. another CNS-illness other than diagnosed depression treated with SSRI or SSRI similar drugs.
    2. liver disease
    3. kidney disease
    4. endocrinological disease other than well controlled hypothyroidism
  • Current or history of chronic or acute pancreatitis
  • Any disease which the investigators believe may affect the study
  • Patients treated with TCA or neuroleptics
  • Known abuse of alcohol or drugs
  • Known allergy to liraglutide or any of the other components (disodium phosphate dihydrate, propylene glycol and phenol)
  • Participation in a clinical trial less than 3 months before inclusion in this study
  • Persons who within a period of the last 2 years have participated in scientific experiments involving the use of isotopes, or who have had greater diagnostic tests performed using applied ionizing radiation
  • If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable
  • Claustrophobia or other missing cooperation
  • Severe overweight > 130kg
  • Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body
  • Significant abnormities in the brain detected by MR scanning
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01469351

Aarhus University
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Principal Investigator: Birgitte Brock, MD phD University of Aarhus
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Aarhus Identifier: NCT01469351     History of Changes
Other Study ID Numbers: 2011-000794-31
Study First Received: November 1, 2011
Last Updated: April 18, 2013

Keywords provided by University of Aarhus:
Alzheimers disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on September 20, 2017